Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that ...

Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.

DUPIXENT supported by positive APG990 interim Phase 1 results ... are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating ...

Dupixent becomes the first-ever targeted therapy ... There is also the prospect of another therapy with a new mechanism of action in the next year or two after Amgen and AstraZeneca’s TSLP ...

Although there is also lebrikizumab from Lilly, lebri targets the IL-13 pathway and therefore, has nearly complete overlap with Dupixent's mechanism of action. For this reason, for patients that ...

but we also acknowledge that as a drug with a novel mechanism and an agent that’s already shown a remittive effect as we’ve shown in the Phase 1b that even efficacy in the range of Dupixent ...

Its mechanism of action (how it works ... 12 years and older who weigh at least 40 kilograms (around 88 pounds). Dupixent, on the other hand, can be used in certain children with this condition ...

Its mechanism means that it provides both bronchodilation ... worldwide sales of Ohtuvayre could top $1.1 billion by 2029. Dupixent up next There could be another important new product approved ...